189 related articles for article (PubMed ID: 34629107)
21. [Elevated levels of dendritic cell-correlated miRNAs in ascites and sera of patients with ovarian cancer].
Wu X; Zhi X; Liu M; Xie J; Zhao S
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Mar; 31(3):383-6. PubMed ID: 25744846
[TBL] [Abstract][Full Text] [Related]
22. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
23. Herpes virus microRNA expression and significance in serous ovarian cancer.
Pandya D; Mariani M; McHugh M; Andreoli M; Sieber S; He S; Dowell-Martino C; Fiedler P; Scambia G; Ferlini C
PLoS One; 2014; 9(12):e114750. PubMed ID: 25485872
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.
Lee H; Park CS; Deftereos G; Morihara J; Stern JE; Hawes SE; Swisher E; Kiviat NB; Feng Q
World J Surg Oncol; 2012 Aug; 10():174. PubMed ID: 22925189
[TBL] [Abstract][Full Text] [Related]
25. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer.
Kan CW; Hahn MA; Gard GB; Maidens J; Huh JY; Marsh DJ; Howell VM
BMC Cancer; 2012 Dec; 12():627. PubMed ID: 23272653
[TBL] [Abstract][Full Text] [Related]
26. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
[TBL] [Abstract][Full Text] [Related]
27. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
[TBL] [Abstract][Full Text] [Related]
28. Comparative expression analysis of tRF-3001a and tRF-1003 with corresponding miRNAs (miR-1260a and miR-4521) and their network analysis with breast cancer biomarkers.
Hussain SA; Deepak KV; Nanjappa DP; Sherigar V; Nandan N; Suresh PS; Venkatesh T
Mol Biol Rep; 2021 Nov; 48(11):7313-7324. PubMed ID: 34661810
[TBL] [Abstract][Full Text] [Related]
29. The Value of Plasma-Based MicroRNAs as Diagnostic Biomarkers for Ovarian Cancer.
Wang W; Yin Y; Shan X; Zhou X; Liu P; Cao Q; Zhu D; Zhang J; Zhu W
Am J Med Sci; 2019 Oct; 358(4):256-267. PubMed ID: 31353030
[TBL] [Abstract][Full Text] [Related]
30. Serum miR-1181 and miR-4314 associated with ovarian cancer: MiRNA microarray data analysis for a pilot study.
Ruan L; Xie Y; Liu F; Chen X
Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():31-38. PubMed ID: 29353130
[TBL] [Abstract][Full Text] [Related]
31. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer.
Hu X; Macdonald DM; Huettner PC; Feng Z; El Naqa IM; Schwarz JK; Mutch DG; Grigsby PW; Powell SN; Wang X
Gynecol Oncol; 2009 Sep; 114(3):457-64. PubMed ID: 19501389
[TBL] [Abstract][Full Text] [Related]
32. Circulating microRNA expression profiles in ovarian cancer.
Ayaz L; Çayan F; Balci Ş; Görür A; Akbayir S; Yıldırım Yaroğlu H; Doğruer Unal N; Tamer L
J Obstet Gynaecol; 2014 Oct; 34(7):620-4. PubMed ID: 24911418
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer.
Hong F; Li Y; Xu Y; Zhu L
J Int Med Res; 2013 Feb; 41(1):64-71. PubMed ID: 23569131
[TBL] [Abstract][Full Text] [Related]
34. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer.
Zheng H; Zhang L; Zhao Y; Yang D; Song F; Wen Y; Hao Q; Hu Z; Zhang W; Chen K
PLoS One; 2013; 8(11):e77853. PubMed ID: 24223734
[TBL] [Abstract][Full Text] [Related]
35. The microRNA miR-192/215 family is upregulated in mucinous ovarian carcinomas.
Agostini A; Brunetti M; Davidson B; Tropé CG; Eriksson AGZ; Heim S; Panagopoulos I; Micci F
Sci Rep; 2018 Jul; 8(1):11069. PubMed ID: 30038317
[TBL] [Abstract][Full Text] [Related]
36. A novel serum microRNA panel to discriminate benign from malignant ovarian disease.
Langhe R; Norris L; Saadeh FA; Blackshields G; Varley R; Harrison A; Gleeson N; Spillane C; Martin C; O'Donnell DM; D'Arcy T; O'Leary J; O'Toole S
Cancer Lett; 2015 Jan; 356(2 Pt B):628-36. PubMed ID: 25451316
[TBL] [Abstract][Full Text] [Related]
37. Expression of the miR-200 family in tumor tissue, plasma and urine of epithelial ovarian cancer patients in comparison to benign counterparts.
Savolainen K; Scaravilli M; Ilvesmäki A; Staff S; Tolonen T; Mäenpää JU; Visakorpi T; Auranen A
BMC Res Notes; 2020 Jul; 13(1):311. PubMed ID: 32611374
[TBL] [Abstract][Full Text] [Related]
38. The differential expression of miRNAs between ovarian endometrioma and endometriosis-associated ovarian cancer.
Nakamura N; Terai Y; Nunode M; Kokunai K; Konishi H; Taga S; Nakamura M; Yoo M; Hayashi M; Yamashita Y; Ohmichi M
J Ovarian Res; 2020 May; 13(1):51. PubMed ID: 32359364
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-200c and microRNA-31 regulate proliferation, colony formation, migration and invasion in serous ovarian cancer.
Ibrahim FF; Jamal R; Syafruddin SE; Ab Mutalib NS; Saidin S; MdZin RR; Hossain Mollah MM; Mokhtar NM
J Ovarian Res; 2015 Aug; 8():56. PubMed ID: 26260454
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer.
Meng X; Müller V; Milde-Langosch K; Trillsch F; Pantel K; Schwarzenbach H
Oncotarget; 2016 Mar; 7(13):16923-35. PubMed ID: 26943577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
